Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth
Targeting mitochondrial metabolism in cancer cells has shown promising therapeutic potential. Here, the authors screen FDA-approved compound library and show that the β1-blocker nebivolol inhibits oxidative phosphorylation and angiogenesis in cancer cells and can be re-purposed for cancer therapy.
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-17384-1 |